TSX runs higher on rate cut expectations
DUBLIN - Investment firm Citadel Group has disclosed a 2.1% ownership position in Mural Oncology plc, according to a regulatory filing published Monday.
The disclosure, made under Irish Takeover Panel rules, reveals that Citadel holds 364,941 shares representing approximately 2.1% of the biopharmaceutical company, while also maintaining short positions equivalent to 1.24% of the company’s shares.
According to the filing, Citadel’s position includes 336,941 owned or controlled shares, along with stock-settled derivatives covering an additional 28,000 shares. The firm’s short positions primarily consist of stock-settled derivatives for 215,100 shares.
The disclosure details multiple transactions conducted on August 22, including both purchases and sales of common stock at prices ranging from $2.07 to $2.08 per share. The largest single transaction was a sale of 33,732 shares at $2.07.
The filing also reveals options activity, including the purchase of put options and the sale of call options at various strike prices and expiration dates extending through January 2027.
Irish takeover rules require public disclosure when an entity’s interest in a company reaches or exceeds 1% of relevant securities. The information was submitted through a Form 8.3 filing, which is required for opening position disclosures under Irish regulations.
Mural Oncology, listed on the Irish stock exchange, focuses on developing cancer therapeutics. The company has not commented on Citadel’s position as reported in the regulatory filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.